Bortezomib

Also known as: Velcade, PS-341, MG-341, MLN341, LDP 341, NSC 681239, DPBA, Radiciol, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid

Bortezomib (CAS 179324-69-7) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C19H25BN4O4 and a molecular weight of 384.237 g/mol. Key properties include a melting point of 122-124°C and a density of 1.2±0.1 g/cm3. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 179324-69-7
Jingsj CID: J-2322-3
Molecular Formula: C₁₉H₂₅BN₄O₄
Molecular Weight: 384.237 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	122-124°C
Density	1.2±0.1 g/cm3
Exact Mass	384.196899
PSA	124.44000
LogP	2.45
Refractive Index	1.564
Storage Conditions	Hygroscopic, -20°C Freezer, Under Inert Atmosphere
Stability	Hygroscopic and Moisture Sensitive

Activity & Biological Data

Target	Ki: 0.6 nM (20S proteasome)[1]
Additional Information	[1]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [2]. Boccadoro M, et al. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005 Jun 1;5(1):18. [3]. Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3(2):333-9. [4]. Yamamoto S, et al. Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats. J Pharmacol Sci. 2015 Sep;129(1):43-50.

Target

Ki: 0.6 nM (20S proteasome)[1]

Additional Information

[1]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [2]. Boccadoro M, et al. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005 Jun 1;5(1):18. [3]. Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3(2):333-9. [4]. Yamamoto S, et al. Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats. J Pharmacol Sci. 2015 Sep;129(1):43-50.

Customs & Trade Information

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Frequently Asked Questions

What is the CAS number of Bortezomib?

The CAS number of Bortezomib is 179324-69-7.

What are the molecular formula and molecular weight of Bortezomib?

Bortezomib has molecular formula C19H25BN4O4 and molecular weight 384.237 g/mol.

What are the upstream and downstream products of Bortezomib?

For Bortezomib, Upstream Products: (1R)-(1S,2S,3R,5S)-Pinanediol-N-(N-pyrazinylphenylalaninoyl)-1-amino-3-methyl-butane-1-boronate, 2-Pyrazinecarboxylic acid, N-Benzyloxycarbonyl-L-phenylalanine; Downstream Products: (S)-3-Phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoic acid.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Bortezomib (CAS 179324-69-7)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-2322-3 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.